Skip to main content
OpenTrials
Completed

NCT Number: NCT03989297

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasopharyngeal Carcinoma Carcinoma Head and Neck Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kiang Wu Hospital

Macao, 999078, China

About this study

NPC is a common type cancer in Macau and Southern China. The role of PD-L1 in NPC remains controversial. There many reasons behind these inconsistent findings. We used the SP263 antibody with the standard cut off value of 1% and 5%, which is frequently used for lung cancer and other cancer types. We also plan to include over 150 patients, which will be the largest study in NPC. This will help us to gain insights in NPC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Above 18 years of age
  • Locally advanced (stage IIIB) or metastatic (stage IV) NPC
  • Fresh-frozen tissue samples were available were included
  • After treatment with curative surgery or radiotherapy in Macau
  • With follow up data were available

Exclusion criteria

  • Enrolment in studies that prohibit any participation in this observational study

Treatment and study plan

Radiation

Radiation

Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.

Primary outcomes

  1. Response rate

    Time frame: Followed up with 12 months after last patient in

    Efficacy after radiation

Secondary outcomes

  1. Survival rate

    Time frame: Followed up with 12 months after last patient in

    Survival in PD-L1 positive and negative group

Sponsors and collaborators

Lead sponsor

Kiang Wu Hospital

Other

Registry information

Official study title

Expression and Clinical Significance of PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

Important dates

Study start
2017
Primary completion
2019
Study completion
2019
First posted
Jun 18, 2019
Registry last updated
Sep 2, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.